Skip to content
Our Latest News, Case Studies, Webinars & More
Ethixbase360 and Veresure Announce Strategic Partnership to Strengthen Third-Party Risk Management and Supply Chain Integrity Amid Growing Global Compliance Demands
17 November 2025 — Ethixbase360, a global leader in third-party risk management and supply chain transparency solutions,[...]
The Role of Enhanced Due Diligence in Pharma M&A
Mergers and acquisitions in the life sciences sector can rapidly expand a company’s scientific capabilities, geographic reach, and market access — but[...]
Navigating the New BIS Landscape: Why a Risk-Based Approach Matters More Than Ever
The U.S. Department of Commerce’s Bureau of Industry and Security (BIS) has long used the Entity List to restrict exports to organizations and individuals engaged in activities contrary to U.S. [...]
What the new BIS 50% Rule Means for Third-Party Screening & Ownership Due Diligence
On September 29, 2025, the Bureau of Industry and Security of the US Department of Commerce (“BIS”) issued a new interim final rule [...]
The Importance of TPRM in Facilitating Ethical Transactions with HCPs
In the Life Sciences industry, maintaining ethical and transparent relationships with healthcare professionals (HCPs) is fundamental to trust, patient safety, and business integrity. [...]
Agility, Innovation & Strong (Ethical) Foundations
Earlier this month, Ethixbase360 was delighted to sponsor the third annual Risk & Compliance Pharma & Life Sciences Conference, held in London. [...]
The Case for Integrity: How SMEs Can Leverage Ethical Business Practices for Growth
In today’s business environment, where regulators and customers are increasingly vigilant about transparency and integrity, ethical business practices have shifted from a compliance
Pharma & Life Sciences 2025 Industry Outlook: Navigating Third-Party Risk in a Shifting Landscape
Pharma & Life Sciences 2025 Industry Outlook: Navigating Third-Party Risk in a Shifting Landscape The pharmaceutical and life sciences industry […]